(Q39345414)

11 September 2017

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors (English)

1 reference

11 September 2017

angiogenesis inhibitor

1 reference

9

Napoleone Ferrara

1 reference

11 September 2017

Alicia S Chung

1

1 reference

11 September 2017

Marcin Kowanetz

2

1 reference

11 September 2017

Xiumin Wu

3

1 reference

11 September 2017

Guanglei Zhuang

4

1 reference

11 September 2017

Hai Ngu

5

1 reference

11 September 2017

David Finkle

6

1 reference

11 September 2017

Laszlo Komuves

7

1 reference

11 September 2017

Franklin Peale

8

1 reference

11 September 2017

3 July 2012

1 reference

11 September 2017

1 reference

11 September 2017

227

1 reference

11 September 2017

404-416

1 reference

11 September 2017

4

1 reference

Vascular endothelial growth factor: basic science and clinical progress

11 September 2017

1 reference

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

Targeting the tumour vasculature: insights from physiological angiogenesis

21 January 2018

1 reference

VEGF inhibition: insights from preclinical and clinical studies

21 January 2018

1 reference

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice.

21 January 2018

1 reference

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

21 January 2018

1 reference

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

Angiogenesis and tumor metastasis

21 January 2018

1 reference

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling

21 January 2018

1 reference

Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house?

21 January 2018

1 reference

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

VEGF receptor signalling - in control of vascular function

21 January 2018

1 reference

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

21 January 2018

1 reference

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

21 January 2018

1 reference

Hypoxia-induced apoptosis and tube breakdown are regulated by p38 MAPK but not by caspase cascade in an in vitro capillary model composed of human endothelial cells.

21 January 2018

1 reference

Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis

21 January 2018

1 reference

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice

21 January 2018

1 reference

The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease

21 January 2018

1 reference

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

21 January 2018

1 reference

Pericytes limit tumor cell metastasis

21 January 2018

1 reference

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

21 January 2018

1 reference

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

21 January 2018

1 reference

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

21 January 2018

1 reference

Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models

21 January 2018

1 reference

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

21 January 2018

1 reference

Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes

21 January 2018

1 reference

The role of adherens junctions and VE-cadherin in the control of vascular permeability

21 January 2018

1 reference

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

21 January 2018

1 reference

PlGF blockade does not inhibit angiogenesis during primary tumor growth

21 January 2018

1 reference

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

21 January 2018

1 reference

Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy

21 January 2018

1 reference

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.4052

1 reference

11 September 2017

1 reference